FTC Seeking Public Comment on Follow-On Biologics

The Federal Trade Commission (FTC) is seeking public comment on follow-on biologics.

In addition, the FTC will hold a public workshop on December 1oth.

The Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition

The  Federal Trade Commission announces it will hold a workshop to explore  competition issues involving biologic medicines and follow-on biologics. As  described in the Federal Register Notice, the workshop will focus on a few key  issues, inter alia:

  • The potential impact of state regulations affecting competition.
  • How regulations, if necessary, might be structured to facilitate competition  while still protecting patient health and safety.
  •   How naming may affect competition.
  • The experience of other countries with follow-on biologic competition.

The  Federal Register Notice poses a series of questions about which the FTC seeks  public comment. The FTC will take these comments into account in its  examination of these topics.

Previous Biologics Workshops and Report:

Event Details

WHEN:

December 10, 2013 Time: 9am – 5pm

WHERE:

FTC Conference Center

601 New Jersey Avenue, NW

Washington, DC

Learn more at http://www.ftc.gov/opp/workshops/biologics/#nj

2013 BIO Fly In – AZBio’s update from Capitol Hill

Last week, over 200 leaders from across the nation visited Washington D.C. to meet with their Congressional delegations and share ideas with our nation’s leaders on the importance of our bioindustry and on the issues that are key to moving innovation forward and providing access to these life sustaining and life saving innovations.Continue reading

BioCentury This Week: On The Brink of Disunioun

When President Obama delivers the State of the Union address on Tuesday, he’ll be speaking to a polarized Congress where brinksmanship is the order of the day.  If lawmakers don’t act by March 1, budget sequestration will slash funding for biomedical research and oversight of the nation’s food and drug products. Continue reading